Financial Data and Key Metrics Changes - For the full year 2025, the company achieved 100% year-over-year growth with an adjusted EBITDA margin of 13%, a positive GAAP operating margin, and positive cash flow [6][26] - Total revenue in Q4 2025 was $96.1 million, representing a 113% year-over-year increase, with prenatal revenue at $86.9 million (up 98%) and oncology revenue at $9.1 million (up 736%) [29][21] - Gross margins improved to 71.4% in Q4 2025, a 14.3 percentage point increase year-over-year [25][31] Business Line Data and Key Metrics Changes - Test volumes grew by 51% year-over-year, reaching approximately 170,000 tests in Q4 2025 [20][33] - The average selling price (ASP) increased by 35% year-over-year to $495 for the full year 2025, with a significant sequential increase of $60 per test in Q4 [23][34] - Oncology revenue growth was driven by the adoption of Northstar Select and Response, with a quarter-over-quarter growth of 29% excluding true-up revenue [22][30] Market Data and Key Metrics Changes - The company reached an annualized revenue run rate of $384 million in Q4 2025, indicating strong market demand and growth potential [10][21] - The company has secured Medicare coverage for Northstar Select and signed contracts covering over 250 million lives in the U.S. [8][10] Company Strategy and Development Direction - The company aims to build a category-defining business and enter the S&P 500, focusing on innovation in prenatal and oncology diagnostics [11][46] - The launch of new products, including expanded fetal antigen NIPT and Northstar Select PGx, is expected to drive future growth [12][40] - The company emphasizes operational efficiency and cost reduction, achieving GAAP profitability while maintaining high growth rates [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, citing strong test volume momentum and the impact of new clinical guidelines on market adoption [37][38] - The company anticipates that the recent contract with UnitedHealthcare will enhance ASPs and reduce friction in patient access to tests [42][63] - Management believes that the current guidance for 2026 is conservative, with several growth drivers not fully reflected in the projections [35][79] Other Important Information - The company ended 2025 with approximately $496 million in cash and only $50 million in term debt, positioning it well for future growth [34][35] - The company achieved a significant milestone by going public during a challenging market environment, demonstrating resilience and execution capability [5][6] Q&A Session Summary Question: Awareness of UNITY among providers - Management noted that around 50% of providers are unaware of UNITY, indicating significant growth potential as awareness increases [49][50] Question: Conversations with health systems regarding MFMs - Management highlighted the importance of MFMs in driving test adoption and the ongoing discussions to increase uptake among larger health systems [52][53] Question: New provider metrics for Northstar - Management reported a record increase in active ordering providers in Q4, signaling strong growth potential for Q1 2026 [56][58] Question: Gross margin expectations - Management indicated that gross margins are expected to remain stable in the high 60% to low 70% range, without aggressive expectations for expansion [60] Question: Impact of UnitedHealthcare contract - Management expects higher ASPs from the in-network contract with UnitedHealthcare, which covers both prenatal and oncology products [63][65] Question: Competitive landscape and impact from Natera - Management stated that they have not seen any negative impact from competition, as evidenced by strong test volume growth and increased prenatal revenues [68]

Core Viewpoint - BillionToOne, a molecular diagnostics company, is set to raise $200 million through its IPO by offering 3.8 million shares priced between $49 and $55 per share, resulting in a fully diluted market capitalization of $2.7 billion at the midpoint of the proposed price range [1][2] Company Overview - Founded in 2016, BillionToOne focuses on prenatal screening and cancer treatment monitoring, utilizing its Quantitative Counting Templates technology to detect DNA molecules with single-base pair precision [2] - The company plans to list on NASDAQ under the ticker symbol BLLN, with joint bookrunners including JPMorgan, Jefferies, Wells Fargo Securities, and BTIG [2] Product Development - BillionToOne has developed a single-molecule next-generation sequencing (smNGS) platform for prenatal and oncology products, allowing significant insights through simple blood collection [1] - In 2019, the company launched its first prenatal product, UNITY, which is a non-invasive prenatal test for assessing the risk of recessive genetic diseases without requiring paternal samples or invasive procedures [1] - In 2023, BillionToOne introduced two complementary pan-cancer liquid biopsy tests: Northstar Select for guiding treatment choices and Northstar Response, a methylation-based test that quantifies cancer severity at the single-molecule level without tissue biopsy [1] Financial Performance - For the 12 months ending June 30, 2025, BillionToOne reported revenue of $209 million [2]

Core Insights - BillionToOne, a molecular diagnostics company, has filed for an IPO to raise up to $100 million [1][2] - The company focuses on developing prenatal and oncology diagnostic technologies using its single-molecule next-generation sequencing (smNGS) platform [1] Company Overview - Founded in 2016 and headquartered in Menlo Park, California, BillionToOne reported revenue of $209 million for the 12 months ending June 30, 2025 [2] - The company plans to list on the NASDAQ under the ticker symbol "BLLN" [2] Product Development - In 2019, BillionToOne launched its first prenatal testing product, UNITY, which is the world's first non-invasive prenatal testing technology based on cell-free DNA [1] - In 2023, the company introduced two complementary liquid biopsy products: Northstar Select for treatment guidance and Northstar Response, which quantifies cancer burden at the single-molecule level without tissue biopsy [1]